Patsnap

Simplifying the complex to transform ideas into reality with our AI-powered intelligence products.

[Patsnap @Patsnap]

If patents are “for the weak,” as Elon Musk claims, why is he patenting his inventions? In this article, we’ll take an in-depth look at Musk’s IP strategy and patent portfolios: https://t.co/dG4RFmkZdX

#ElonMusk #Tesla #patentportfolio

[Patsnap @Patsnap]

Today we're releasing the 2026 R&D Benchmark Report: Waste, AI and the Race to Market. 🚀

We surveyed 200+ senior R&D leaders at organizations spending $50M+ annually.

What they shared was candid.

73% say half or fewer of their projects ever reach market. 37% are spending up to 40% of their budget on work that never launches. 92% are using AI. And yet nearly half say better intelligence access would still be their biggest productivity gain.

The report breaks down where the waste is coming from, why the intelligence gap persists, and what the highest-performing teams are doing differently. 💡

Get your copy here: https://t.co/Q6U8BBwHb1

#RD #Innovation #BenchmarkReport #IPStrategy #AIinRD #Patsnap #2026RandDBenchmark

[Patsnap @Patsnap]

Biological sequence searches can get messy fast, especially when you’re juggling fragmented workflows, rigid tools, and the pressure to connect sequences to IP, without missing a single insight.

Join us for Bio Essentials: Speed Up Sequence Analysis & Discover What Matters Faster.

📆 09 June, 2026
🕐 10:00 AM EST | 3:00 PM BST

In this session, we’ll show you how to move beyond slow, manual workflows. Learn how to search sequences with precision, pinpoint exact records within seconds using our Sequence Assistant, and leverage the Antibody R&D module to uncover antibody-antigen relationships you might otherwise miss. Stop hunting for data and start driving innovation with confidence.

Save your spot: https://t.co/9VVhprRlbG

#IPAnalytics #SequenceAnalysis #Biotech #AntibodyDiscovery #PatentData #RAndD #PatSnap #Webinar

[Patsnap @Patsnap]

🚀 We just got back from Antibody Engineering in Therapeutics 2026!

From in silico antibody discovery to hit-to-lead optimization, the field is moving fast. What stood out most? The growing demand for high-quality, validated antibody-antigen data at scale, exactly what we've been building toward.

We came away buzzing with insights and ideas, and we can't wait to share what we learned with you. Stay tuned, a deeper dive into our key takeaways is coming soon.

Couldn't make it this year? We'd love to connect. Reach out to us directly, let's keep the conversation going. 💬

#AntibodyEngineering #Therapeutics2026 #Biotech #DrugDiscovery #Antibodies

[Patsnap @Patsnap]

Finding the right material candidates can get messy fast, especially when you’re juggling specific performance requirements, fragmented supplier data, and the need to assess novelty across global IP.

Join us for PatSnap Eureka Materials: Enhance Your Solution by Locating the Right Material.

📆 02 June, 2026
🕐 10:00 AM EST | 3:00 PM BST

In this session, we’ll show you how to move beyond slow, manual material scouting. Learn how to identify candidates based on your exact performance metrics, streamline procurement by instantly mapping supplier landscapes, and leverage our new formulation agent to bring all your R&D data together. Stop hunting for data and start building better solutions with confidence.

Save your spot: https://t.co/amdd4aDLC8

#IPAnalytics #MaterialsScience #RandD #Innovation #PatentData #SupplyChain #PatSnap #Webinar

[Patsnap @Patsnap]

We're heading to Basel for Antibody Engineering & Therapeutics Europe 2026! 🇨🇭🔬

Our team, Heather Allen, Ben Coverdale, and Fraser Ghai will be at booth #15, ready to show how PatSnap can accelerate your in silico antibody discovery, from target identification to lead optimization, with the data infrastructure to back every decision.

Planning to attend? Drop a comment or message us, we’d love to connect and say hello in person!

#AET2026 #Biologics #AssetPrioritization #RiskMitigation #IPStrategy #LifeSciences #PatSnap

[Patsnap @Patsnap]

We're heading to Basel for Antibody Engineering & Therapeutics Europe 2026! 🇨🇭🔬

Our team, Heather Allen, Ben Coverdale, and Fraser Ghai will be at booth #15, ready to show how PatSnap can accelerate your in silico antibody discovery, from target identification to lead optimization, with the data infrastructure to back every decision.

Planning to attend? Drop a comment or message us, we’d love to connect and say hello in person!

#AET2026 #Biologics #AssetPrioritization #RiskMitigation #IPStrategy #LifeSciences #PatSnap

[Patsnap @Patsnap]

It's not just better science driving the GLP-1 revolution, it's smarter strategy. 🧠

Learn how fast-follow innovation is powering the next wave of metabolic therapies, from Pfizer's foundational small-molecule research to cutting-edge programs at AstraZeneca, Merck, and Eli Lilly. 💊

PatSnap's GLP-1 Market Landscape report unpacks the IP strategy, licensing deals, and clinical data behind a $100B therapeutic space. Watch to find out how innovation really scales.

Download the full report for free: https://t.co/g1kJAeIORh

#GLP1 #DrugDiscovery #Innovation #PatSnap #Innovation #Ozempic

[Patsnap @Patsnap]

We've spent nearly two decades building the world's most comprehensive innovation intelligence dataset. Now, we're making it more accessible than ever.

We have expanded access to PatSnap Eureka, our agentic AI platform for R&D and IP teams, with free self-serve trial access, new APIs, and Model Context Protocol (MCP) integrations that bring our proprietary data directly into the AI environments your teams already use, including Claude, ChatGPT, and Cursor.

Because AI is only as valuable as the data behind it. PatSnap's specialized innovation intelligence layer is designed to power higher-quality outputs where general-purpose models fall short.

Read the full update: https://t.co/FvOv3nK4yO

#AI #InnovationIntelligence #RDStrategy #IPStrategy #EnterpriseAI #PatSnap

[Patsnap @Patsnap]

The best innovators don't just have great ideas. They have the intelligence to move on them first. 🌍

18,000+ enterprises, law firms, and research institutions across 50+ countries trust PatSnap to make that happen. Faster insights, smarter decisions, at every stage of the innovation lifecycle.

Built on the world's largest innovation dataset, this is what decision-grade innovation intelligence looks like. 👇

#PatSnap #InnovationIntelligence #AI #IPManagement #RandD #Innovation

[Patsnap @Patsnap]

In May 2024, a rescue dog named Rosie was given months to live. Her owner was told there was nothing more to be done.

He didn't accept that.

Paul Conyngham had no biology background, no lab, no institution behind him. Just a data engineer's instincts and a love for one dog. Over the next year he taught himself computational genomics from scratch, sequenced Rosie's DNA, and designed something nobody had ever built before: a personalized mRNA cancer vaccine for a dog. 🐶🔬

It worked. Six weeks after her first injection the tumors were shrinking. By January she was jumping fences at the dog park chasing rabbits.

But what stayed with us was not the breakthrough. It was the cost of getting there. The months lost to dead ends, the patent wall he hit after two weeks of computation, the right collaborators found only by chance after months of cold emails. There are more people like Paul out there. People with real problems, real capability, and no clear map. To us, that's a problem worth solving. 💡

Read the full story: https://t.co/sgbV0tXmJN

#PatSnap #Innovation #LifeSciences #mRNA #PaulConyngham

[Patsnap @Patsnap]

The biopharma investment landscape has never been more complex or more consequential.

Patent cliffs. Rising R&D costs. M&A deal values that more than doubled in 2025 to $133B. The science behind an asset is increasingly what separates a strong bet from an expensive mistake.

Today, we're announcing that Synapse is now available directly within the FactSet Workstation. Financial professionals can now access biopharma pipeline data, IP positions, clinical activity, and deal intelligence without ever leaving their existing workflow.

Read the full announcement: https://t.co/52AkzDhdgH

#PatSnap #FactSet #Synapse #Biopharma #LifeSciencesInvesting

[Patsnap @Patsnap]

💉 GLP-1 innovation isn't slowing down. We're only just beginning to see the economic and cultural impact of Ozempic and it's generic counterparts.

The innovators who stand to benefit most are those who realize Ozempic is just the beginning. Read our latest article to see where the industry leaders are headed next, featuring insights from our GLP Market Landscape Report.

🔗 https://t.co/uUFRk0D7rj

#PharmaInnovation #GLP1 #HealthcareTrends #Ozempic

[Patsnap @Patsnap]

Innovation Spotlight 🚀

This week marks a significant milestone in Canada’s pharmaceutical landscape: the approval of the first generic alternative to Ozempic. This is just the beginning.

🔗 https://t.co/FBRgSqunl0

As GLP-1 therapies continue to reshape the market, increased competition is set to drive accessibility, pricing dynamics, and innovation across the space.

Curious about what’s next? Check out the GLP-1 Market Landscape report in the comments to explore emerging players, pipeline developments, and where the future is headed.

#PharmaInnovation #GLP1 #HealthcareTrends #Ozempic

[Patsnap @Patsnap]

🧭 AI maps the landscape. Humans choose the destination. Teams that combine both move faster.

🔗 Stop asking the wrong questions: https://t.co/svbXIQbYHY

#AITools #InnovationStrategy #ProductDevelopment #TechInsights

[Patsnap @Patsnap]

Can AI truly innovate, or are we asking the wrong question? The real impact of AI may not be what it creates, but how much it accelerates human innovation when used correctly.

🔗 Read the full article: https://t.co/hKuNwVCd7M

#Innovation #AIFacts #RandD #Leadership

[Patsnap @Patsnap]

We're thrilled to announce our partnership with AEVO! 🌎

PatSnap's Find Solutions AI agent is now embedded directly inside AEVO Innovate, the leading innovation management platform for enterprise teams across Latin America.

R&D teams have always had great ideas. What's been missing is a fast, structured way to validate them against prior art, map technical trade-offs, and build a clear path to execution. That's exactly what Find Solutions brings, now living natively inside the platform teams already use every day.

Latin America's innovation market is one of the fastest-growing in the world, and this is our first integration partnership in the region. We couldn't be more excited to be part of that momentum alongside the AEVO team. 🙌

Read the full story: https://t.co/jEKI7iJy1f

#PatSnap #AEVO #LatinAmerica #Innovation #RD #AIAgents #IPIntelligence

[Patsnap @Patsnap]

Patent searches shouldn't result in data overload. When traditional workflows fail to keep up with real-time changes, teams fall out of sync, leading to duplicate work and missed insights.

Join us for Analytics Essentials: Optimize Data Review and Improve Collaboration.

📆 21 May, 2026
🕐 10:00 AM EST | 3:00 PM BST

In this session, we’ll show you how to move away from fragmented workflows and into a centralized workspace. Learn how to aggregate annotations, automate real-time document refreshes, and set up email alerts so your team is always working from the most current data. Stop re-organizing information and start accelerating your strategic IP decisions.

Save your spot: https://t.co/pu1UljZ0Zb

#IPAnalytics #PatentReview #Collaboration #InnovationStrategy #PatSnap #Workflows #Webinar

[Patsnap @Patsnap]

Rory McIlroy just won back-to-back Masters. While the world watched the swing, we saw something else. Every club in that bag, every dimple on that ball, every groove on that clubface is protected IP. The best in the world don't leave anything unprotected. 🏌️⛳

How many patents do you think are in his bag?

#patents #innovation #IP #intellectualproperty #Masters2026 #RoryMcIlroy #golf

[Patsnap @Patsnap]

China had 947 GLP-1 clinical trials in 2025. The US had 1,034.

For a market most Western pharma teams still treat as secondary, that's a striking number. And it's not being driven by generics alone. 💊

Jiangsu Hansoh, Hangzhou Sciwind, and PegBio already have approved GLP-1 assets. Huadong Medicine, Innovent Biologics, and Tonghua Dongbao are deep in advanced clinical stages.

Global pharma has taken notice. AstraZeneca paid $185M upfront to license ECC5004 out of China. Amgen brought MariTide into Chinese trials to lock in a first-in-class position.

With semaglutide patents already expiring in China and India, the generics wave has started. The companies investing in next-generation assets right now are positioning for what comes after it.

APAC isn't the next frontier for GLP-1 innovation. It already is one. 🌎

Our 2026 GLP-1R Market Landscape Report covers the full picture. Download here: https://t.co/f64CthcF77

#GLP1 #GLP #Ozempic #NovoNordisk #Innovation #Science #DrugDevelopment #DrugDiscovery #Biopharma

[Patsnap @Patsnap]

Everyone knows GLP-1 drugs are changing medicine. But fewer people are talking about what's actually powering the race behind the scenes. 👩‍🔬

It's called fast-follow innovation. Companies analyze existing molecules, patents, and clinical data, then move quickly to improve on what works. Pfizer's early small-molecule research may have ended, but it sparked a wave of next-generation candidates now driving programs at AstraZeneca, Merck, and Hansoh.

Our latest report gives you the full picture. 🔬

Download for free: https://t.co/J6wc9RhJDF

#GLP1 #Ozempic #Innovation #DrugDiscovery #GLP